Aratana Therapeutics Inc. (PETX) Insider Ernst Heinen Sells 10,000 Shares
Aratana Therapeutics Inc. (NASDAQ:PETX) insider Ernst Heinen sold 10,000 shares of the stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $10.00, for a total transaction of $100,000.00. Following the transaction, the insider now owns 115,494 shares of the company’s stock, valued at approximately $1,154,940. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) opened at 10.04 on Thursday. Aratana Therapeutics Inc. has a 52 week low of $2.56 and a 52 week high of $10.73. The stock’s market capitalization is $355.57 million. The company has a 50-day moving average of $9.24 and a 200-day moving average of $7.30.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.37. The business earned $38.05 million during the quarter, compared to the consensus estimate of $15.14 million. Aratana Therapeutics had a negative return on equity of 17.53% and a negative net margin of 166.67%. During the same period in the previous year, the company posted ($0.23) EPS. On average, analysts anticipate that Aratana Therapeutics Inc. will post ($0.77) EPS for the current year.
A number of equities analysts have weighed in on the stock. Lake Street Capital reiterated a “buy” rating and set a $15.00 target price on shares of Aratana Therapeutics in a research report on Tuesday, September 6th. Jefferies Group began coverage on shares of Aratana Therapeutics in a report on Friday, August 19th. They issued a “buy” rating and a $13.00 price target on the stock. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a report on Wednesday, August 17th. Barclays PLC lowered their price target on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $11.00 price target on shares of Aratana Therapeutics in a report on Wednesday, August 10th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Aratana Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $11.28.
Several large investors have recently added to or reduced their stakes in PETX. Metropolitan Life Insurance Co. NY purchased a new stake in Aratana Therapeutics during the second quarter worth about $162,000. First Light Asset Management LLC increased its stake in Aratana Therapeutics by 52.9% in the second quarter. First Light Asset Management LLC now owns 684,921 shares of the biopharmaceutical company’s stock worth $4,329,000 after buying an additional 236,915 shares in the last quarter. A.R.T. Advisors LLC increased its stake in Aratana Therapeutics by 81.5% in the second quarter. A.R.T. Advisors LLC now owns 71,515 shares of the biopharmaceutical company’s stock worth $451,000 after buying an additional 32,111 shares in the last quarter. Bridgeway Capital Management Inc. increased its stake in Aratana Therapeutics by 85.1% in the second quarter. Bridgeway Capital Management Inc. now owns 86,983 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 40,000 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its stake in Aratana Therapeutics by 16.6% in the second quarter. Parametric Portfolio Associates LLC now owns 27,958 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 3,989 shares in the last quarter. Institutional investors and hedge funds own 85.56% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.